Purpose: To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-corrected visual acuity (BCVA) outcomes over 2 years.
N eovascular age-related macular degeneration (AMD) is characterized by new vessel growth and leakage in the choroidal vascular network beneath Bruch membrane. Although the pathologic events that precede choroidal neovascularization (CNV) are not clearly understood, disrupting activity of vascular endothelial growth factor A (VEGF-A), a diffusible cytokine that promotes angiogenesis and vascular permeability, is an effective strategy for treating CNV secondary to AMD. Ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) is a humanized, affinity-matured, anti-VEGF antigen-binding fragment (Fab) that binds to and neutralizes all isoforms of VEGF-A and their biologically active degradation products. In two pivotal Phase III trials-Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab In the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) 1 and Anti-Vascular Endothelial Growth
Factor Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-related Macular Degeneration (ANCHOR) 2 -monthly intravitreal injections of 0.3 mg or 0.5 mg of ranibizumab not only prevented vision loss but also improved bestcorrected visual acuity (BCVA) on average. Furthermore, ranibizumab treatment was associated with significant reductions in retinal thickness, arrested growth of CNV lesions, and caused cessation of leakage from CNV, in many cases as early as 1 week after the treatment initiation. These anatomical (and BCVA) improvements were maintained with monthly dosing.
Subsequently, the Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization With or Without Classic CNV Secondary to AgeRelated Macular Degeneration (PIER) evaluated the safety and efficacy of an alternative dosing regimen of ranibizumab (i.e., 3 monthly loading doses followed by quarterly doses). A primary analysis of PIER data 3 indicated that the PIER dosing regimen was effective for treating eyes with neovascular AMD, with treated eyes losing significantly fewer BCVA letters compared with control eyes at the Month 12 evaluation. However, the magnitude of the benefit observed with quarterly dosing was disappointing compared with that observed with monthly dosing in the MARINA and ANCHOR studies.
Since U.S. Food and Drug Administration approval of ranibizumab in 2006, it has become apparent to clinicians that some patients with neovascular AMD do well with few injections, while many require monthly or near monthly dosing to maintain anatomical and visual acuity gains. 4, 5 Despite the lack of validation from Level I trials that anatomical criteria can be used as a surrogate for BCVA outcomes, most clinicians use them (e.g., optical coherence tomography [OCT] or fundus fluorescein angiography [FFA] ) to help determine retreatment schedules.
Although subgroup analyses of the MARINA and ANCHOR trials 6, 7 showed that nearly all eyes did well with monthly ranibizumab therapy (both visually and anatomically), those data provided little information about which eyes would do well with less frequent treatment or if anatomical data correlated with BCVA outcomes. The PIER trial was unique in that it was a controlled clinical trial of an efficacious drug that was dosed too infrequently for the average patient with AMD; most eyes experienced recurrent retinal edema and loss of BCVA gains once monthly therapy was discontinued. In the current analysis, we tested the hypothesis that inactivity (a dry macula) on OCT and FFA is associated with the maintenance of BCVA gains by retrospectively evaluating the degree to which anatomical features of the study eye early in ranibizumab treatment were predictive of BCVA outcomes at Months 12 and 24 in subgroups of PIER subjects.
Methods

Study Design
PIER methodology, including study design, eligibility, masking, treatment, assessments, and analyses, has been published in detail. 3 The PIER protocol was approved by the appropriate institutional review board at each study site, and all subjects provided written informed consent before study participation.
Subjects
Eligible subjects were $50 years of age with a diagnosis of primary or recurrent subfoveal CNV (predominantly classic, minimally classic, or occult with no classic) secondary to AMD. Classic and occult CNV comprised $50% of the total AMD lesion area, and the total lesion was #12 disk areas (DA). If a CNV lesion was minimally classic or occult with no classic component, the treated eye was required to meet protocoldefined criteria for disease progression (i.e., a 10% increase in lesion size based on FFA obtained 1 month before study initiation Eyes were excluded if they had been treated for AMD with another antiangiogenic drug, photodynamic therapy, external beam radiation therapy, transpupillary thermotherapy, or subfoveal laser photocoagulation at any time or juxtafoveal or extrafoveal laser photocoagulation within 1 month before Day 0. Exclusion criteria also included structural damage to the central fovea and subretinal hemorrhage $1 DA or $50% of total lesion area with foveal involvement. One eye per subject was studied.
Treatment
Eligible eyes were randomized in the ratio of 1:1:1 to sham injections, 0.3 mg of intravitreal ranibizumab, and 0.5 mg of intravitreal ranibizumab (Figure 1 The PIER protocol mandated that eyes receive sham injections or intravitreal injections of 0.3 mg or 0.5 mg of ranibizumab every month for 3 months (Day 0, Month 1, Month 2) and every 3 months thereafter (Months 5, 8, 11, 14, 17, 20, and 23) for the remainder of the 2-year study. In addition to injection visits, clinic visits were scheduled at Months 3, 12, and 24. However, after careful review of available clinical data, including data from MARINA and ANCHOR, as they became available, it was believed to be in the best interest of sham-group subjects to receive ranibizumab. Thus, in February 2006, the protocol was amended (crossover amendment) to provide shamgroup subjects who completed the Month-12 visit the opportunity to crossover to quarterly injections of 0.5 mg of ranibizumab. Subsequently, after careful review of the 12-month PIER data, it was believed to be in the best interest of all study subjects to be examined and treated more frequently than the protocol mandated. Thus, in August 2006, the protocol was again amended (rollover amendment) to provide all subjects remaining on the study the opportunity to roll over to monthly injections of 0.5 mg ranibizumab for the remainder of the study. No subjects were unmasked to their original treatment assignment as a result of the crossover and rollover amendments.
Assessments
At each scheduled visit, subjects underwent a full ophthalmologic assessment, including BCVA testing with standardized refraction using the ETDRS chart at 4 m. Fundus photography and FFA were performed at screening and at Months 3, 5, 8, 12 
Outcome Measures
The primary efficacy outcome measure of PIER was the mean change from baseline BCVA at Month 12. We performed post hoc analyses of subgroups of ranibizumab-treated eyes (pooled 0.3-mg and 0.5-mg dose groups) defined by FFA, quantitative OCT, and qualitative OCT early in the treatment to determine how those anatomical features correlated with BCVA outcomes at Months 12 and 24, according to the masked assessment by reading center personnel.
Fundus fluorescein angiography. Fundus fluorescein angiography subgroups were composed of eyes that had active FFA lesions (i.e., total area of CNV leakage plus intense progressive retinal pigment epithelium [RPE] staining 6 ¼ 0) and inactive FFA lesions (i.e., total area of CNV leakage plus intense progressive RPE staining = 0). Baseline FFA characteristics assessed included total lesion area categorized as #4 and .4 DA and CNV lesion composition classified as predominantly classic, minimally classic, and occult without classic.
Quantitative optical coherence tomography. Optical coherence tomography subgroups composed of eyes with central foveal thickness (CFT) ,200 mm and CFT $200 mm. Central foveal thickness corresponded to the mean point center thickness as measured by the variable labeled "center" on the fast macular thickness map.
Qualitative optical coherence tomography. As per the PIER protocol, selected study sites submitted horizontal and vertical high-resolution raster lines (512 B-scans per image) in addition to the 128-Bscans-per-image fast macular thickness maps. The 2 high-resolution raster OCT scans per eye per visit (n = 6088) were qualitatively evaluated by a grader (D.M.B., masked to the treatment and study eye), for evidence of CNV-associated activity, including diffuse edema, intraretinal cysts, subretinal fluid, and sub-RPE fluid/serous pigment epithelial detachment. Subretinal fluid was defined as a dark space between the neurosensory retina and the RPE. Sub-RPE fluid was defined as a dark space immediately under the RPE band (see Figure 2 ). Qualitative OCT subgroups were composed of eyes with active OCT lesions (having evidence of any type of fluid on any scan) or inactive OCT lesions (i.e., having no evidence of fluid on any scan).
Statistical Analyses
Baseline FFA characteristics (total lesion area categorized as #4 or .4 DA and lesion composition type) were evaluated for their relationship with BCVA change from baseline at Month 24. Post hoc analyses of mean change from baseline BCVA were performed at specific time points early in the treatment for subgroups defined by FFA (active FFA lesions vs. inactive FFA lesions), quantitative OCT (CFT,200 mm vs. $200 mm), and qualitative OCT (active OCT lesions vs. inactive OCT lesions). Because of the prespecified protocol, only specific visits had FFA and OCT performed. Month 5 and Month 8 were the only data points with both OCT and FFA data that were not immediately preceded by a mandatory injection the month prior. Data were pooled across ranibizumab dose groups, and the last-observation-carried-forward method was used for missing BCVA, FFA, and OCT data. Last observation carried forward was infrequently used, mostly after Month 12. Student t-test, analysis of variance, chi-square, and Pearson and polychoric correlation (observed data) were also used. Polychoric correlation relates an interval outcome with a dichotomous outcome, and its interpretation is similar to that of the Pearson correlation. Stratified tests were used to determine changes in baseline BCVA, CNV plus intense progressive RPE staining, and CFT across time.
Results
Subject Characteristics and Treatment
Between September 2004 and March 2005, 184 subjects were enrolled at 43 U.S. investigative sites and randomly assigned to receive 0.3 mg (n = 60) or 0.5 mg (n = 61) intravitreal ranibizumab or sham injections (n = 63). The treatment groups were balanced on demographic and baseline ocular characteristics (Table 1) . Baseline BCVA for each treatment group was 53 to 56 letters (Snellen equivalent, approximately 20/63 to 20/80). Eighty-one percent of eyes had either occult with no classic or minimally classic CNV lesions. Occult with no classic CNV was more common in the ranibizumab groups (48% in the 0.3-mg group, 49% in the 0.5-mg group) than in the sham-injection group (32%). Seventeen (27.0%) sham eyes, 7 (11.7%) 0.3-mg eyes, and 7 (11.5%) 0.5-mg eyes discontinued from study before Month 24. The primary reason for study discontinuation was the subject's decision to do so.
Forty-three (71.7%) 0.3-mg subjects and 44 (72.1%) 0.5-mg subjects who remained on study at the time of the rollover amendment rolled over to receive 0.5 mg ranibizumab monthly, beginning at Month 19. Subjects in the 0.3-mg and 0.5-mg groups received an average of 2.6 (range, 1-5) and 2.5 (range, 1-5) injections of ranibizumab, respectively, after rollover (Table 2) .
At Month 12, BCVA of eyes in the 0.3-mg, 0.5-mg, and sham-treatment groups had decreased an average of 1.6, 0.2, and 16.3 ETDRS letters, respectively (P , 0.0001 each ranibizumab dose vs. sham). At Month 24, BCVA had decreased an average of 2.2 letters (0.3 mg), 2.3 letters (0.5 mg), and 21.4 letters (sham group) from baseline (P , 0.0001 each ranibizumab dose vs. sham; Figure 3 ). In the pooled 0.3-mg and 0.5-mg ranibizumab group, eyes with CNV lesions #4 DA at baseline had a mean change from baseline BCVA at Month 
Quantitative Optical Coherence Tomography
Scans from 42 (66.7%) sham-group eyes, 39 (65.0%) 0.3-mg eyes, and 42 (68.9%) 0.5-mg eyes were evaluated. Central foveal thickness of ranibizumabtreated eyes decreased during the first 3 months, increased slightly from Month 3 to Month 8, and then decreased, for an average decrease of 126 mm (0.3 mg) and 123 mm (0.5 mg) by Month 12 (Figure 6 ). For sham-group eyes, CFT increased slightly during the first 3 months and then decreased for the remainder of the first study year, for an average decrease of 29 mm at Month 12 (P , 0.01 each ranibizumab group vs. sham group).
The subgroup of ranibizumab-treated eyes that had CFT ,200 mm (n = 53) at Month 3 had gained an average of 0.45 letters from baseline at Month 12 and lost an average of 0.25 letters at Month 24, while those that had lesions with CFT $200 mm (n = 24) at Month 3 had lost an average of 2.42 letters at Month 12 and 3.33 letters at Month 24 ( Figure 7A ). Thus, eyes with 
Qualitative Optical Coherence Tomography Analysis
Optical coherence tomography scans were qualitatively evaluated for any evidence of CNV-associated activity (Figure 2) . Differences between the percentage of ranibizumab-treated eyes and sham eyes with inactive OCT lesions across the 2 years of study were statistically significant at Months 1, 2, 3, and 12 (all P values , 0.05) Ranibizumab-treated eyes that had inactive OCT lesions at Month 5 had gained an average of 2.04 letters from baseline BCVA at Month 12 and 3.86 letters at Month 24, while those that had active OCT lesions at Month 5 had lost an average of 1.25 letters at Month 12 and 3.24 letters at Month 24 ( Figure 8C ). Thus, eyes that had inactive OCT lesions at Month 5 had gained an average of 3.29 more letters at Month 12 (P = 0.33) and 7.10 more letters at Month 24 (P = 0.045) compared with those that had active lesions at Month 5.
Ranibizumab-treated eyes that had inactive OCT lesions at Month 8 had gained an average of 3.88 letters from baseline BCVA at Month 12 and 5.5 letters at Month 24, while those that had active OCT lesions at Month 8 had lost an average of 2.0 letters at Month 12 and 4.04 letters at Month 24 ( Figure 8D ). Thus, eyes that had inactive OCT lesions at Month 8 had gained an average of 5.88 more letters at Month 12 (P = 0.09) and 9.54 more letters at Month 24 (P = 0.009) compared with those with active lesions at Month 8.
Correlation of Anatomical Criteria and Best-Corrected Visual Acuity Outcomes
Pearson correlation coefficients of change from baseline leakage plus RPE staining (leakage) at any visit with change from baseline BCVA at the same or later visits ranged from −0.18 (Month 5 FFA and Month The largest negative correlations (showing an association between CFT decreases and BCVA increases) were typically observed at the same visits or visits that were close in time. For both FFA and OCT, correlations of early anatomical change with later BCVA change were slightly negative or positive, indicating no linear relationship between early anatomical improvement and later BCVA improvement.
Correlations were also assessed for change from baseline BCVA at the same or later visits and dichotomized FFA (i.e., active FFA lesions vs. inactive FFA lesions), and separately, with dichotomized qualitative OCT (i.e., active OCT lesions vs. inactive OCT lesions). Polychoric correlations supported the inference that improved BCVA was associated with anatomical dryness (a positive correlation given the dichotomous coding). For example, for over 24 months, polychoric correlation coefficients for FFA and OCT ranged from +0.21 to +0.48 and +0.13 to +0.32, respectively.
Discussion
This study evaluated the degree to which the anatomical characteristics of the study eye early in treatment affected BCVA outcomes in subgroups of ranibizumab-treated PIER study eyes. The findings demonstrate concepts that may help guide clinicians in the use of anti-VEGF agents in neovascular AMD. First and foremost, an initial anatomical (according to FFA and/or OCT analyses) or visual improvement after three monthly ranibizumab injections does not guarantee long-term success. For eyes with FFA lesion activity at Month 3, CFT $200 mm at Month 3, and qualitative OCT activity at Months 2 and Month 3 ( Figures 5A, 7A , and 8A and B, respectively), the average BCVA gain from 3 monthly loading doses of ranibizumab was lost after switching to quarterly dosing, and eyes lost vision compared with baseline at Months 12 and 24. This demonstrates that eyes that experience improvements after three monthly loading doses still need to be closely monitored because many will need frequent retreatment with anti-VEGF therapy. Second, it appears that the longer anatomical improvements were maintained (according to FFA or OCT), the more likely it was that the BCVA benefits of ranibizumab persisted on a quarterly dosing regimen. Eyes with inactive FFA lesions at Month 5 ( Figure 5B ) or inactive OCT lesions at Month 5 ( Figure 8C ) or Month 8 ( Figure 8D ) were much more likely to maintain their BCVA gains (analogous to the entire treated cohorts in MARINA and ANCHOR that had continuous monthly dosing). It is not our belief that this indicates eyes with an anatomical improvement should be observed less frequently or treated less frequently. However, the data imply that analogous to the successful repair of rhegmatogenous retinal detachments, maintained anatomical success (absence of disease activity on OCT or FFA) seems important for BCVA to be gained and maintained.
Qualitative OCT grading revealed that approximately 60% of eyes showed no lesion activity after 2 loading doses of ranibizumab, and this was maintained with a third dose (Figure 9 ). Thus, it may be that the majority of "anatomical responders" or "incomplete anatomical responders" can be determined after 2 doses of ranibizumab. Subsequent to Month 3, when subjects were mandated to switch to quarterly dosing, more than one third of the initial responders demonstrated recurrent activity on OCT at Month 5 and/or Month 8. While the response at Month 12 (after a mandatory injection at Month 11) showed an anatomical success rate similar to that seen after the initial 2 or 3 doses, this did not result in a concomitant rebound in mean BCVA. This implies that the relative undertreatment and resulting anatomical activity resulted in retinal injury and irreversible loss of BCVA gains. Further evidence of this irreversibility is that even though approximately 72% of patients initially randomized to ranibizumab "rolled over" to monthly therapy beginning at Month 19 (and had on average 2.7 injections), there was minimal improvement in mean BCVA (Figure 3) , and despite the best intentions of the rollover amendment, there was a net loss in mean BCVA from baseline to Month 24.
While a surprisingly low number of eyes demonstrated inactive FFA lesions after 3 loading doses of ranibizumab (i.e., 10% at Month 3), eyes with a dry FFA showed the strongest association with BCVA outcomes at Months 12 and 24. At the same 3-month time point, 60% of evaluated eyes were dry on qualitative OCT grading. This disparity may result from the sampling error introduced by having only two scans available for grading (rather than all 6 radial line scans available from a Stratus macular thickness map or the greatly increased sample size of currently available spectral-domain OCT devices). It is also known that an effective RPE pump sometimes keeps the retina dry and gives a "dry" OCT reading, despite active CNV leakage. This may have been the case for approximately 5% of eyes at Day 0, for which no fluid was seen with qualitative OCT analysis by a masked grader.
Comparison of the 12-month and 24-month BCVA outcomes and correlations between anatomical factors raise important implications for the design of clinical trials for neovascular AMD because it appears that the deleterious effects of undertreatment may take longer than 12 months to become evident. While eyes that had inactive FFA lesions at Month 3 had statistically greater gains from baseline BCVA at Month 12, the advantage was lost by Month 24. In contrast, according to qualitative OCT grading at Months 5 and 8, Month 12 BCVA outcomes of the subgroups of eyes with consistently dry OCTs were not statistically different than those with fluid at Months 5 and 8 (P = 0.33 and 0.090, respectively). However, their BCVA outcomes were significantly different at Month 24 (P = 0.045 and 0.0096, respectively). This implies that the resilience of the retina is finite and that it may take time to demonstrate a difference in treatment strategies. This not only justifies the 2-year end point required in U.S. Food and Drug Administration registration trials for AMD therapies but also emphasizes that the 2-year end point of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT): Lucentis-Avastin Trial 4 trial may be critical to see the ultimate effects of a pro re nata (PRN) treatment regimen on BCVA.
The CATT study monthly treatment arms demonstrated that 53% of eyes with monthly ranibizumab and 71% of monthly bevacizumab had fluid at Month 12 on reading center qualitative OCT analysis of all 6 Stratus radial line scans, but overall, the vision gains were excellent in both the groups, 4 indicating that small amounts of fluid may not be deleterious to 12 month BCVA outcomes with monthly therapy. A higher percentage of eyes had fluid on OCT at Month 12 in the CATT PRN arms (71% ranibizumab and 79% bevacizumab), 4 and the overall reduction in BCVA gains at 12 months in these cohorts may be indicative of the deleterious effects of more fluid with PRN therapy. In the PIER study, anatomical characteristics at time points not immediately after monthly doses were the most predictive of BCVA at Months 12 and 24. Analysis of OCT and FFA data available at the time of PRN therapy visits in the CATT study through 24 months (and the ongoing HARBOR 2.0-mg ranibizumab study PRN arms) will help clarify the correlation of OCT fluid and BCVA outcomes because both of these studies have more complete OCT data sets and larger sample sizes.
Some limitations were inherent to our study. The fixed 3-month dosing in PIER is obviously way too long for most patients and allowed more recurrence and persistence of retinal fluid for much longer than a monthly "tight PRN" CATT approach or even a "treat-and-extend" regimen. The PIER dosing regimen probably exaggerated the deleterious effects of fluid in the retina, and as such, it may not be applicable to smaller excursions of retinal thickness seen with tight PRN or treat-and-extend regimens. Also, anatomical subgroups were limited because OCT data were available for only about two thirds of eyes during the first year of study. Additionally, qualitative OCT evaluation might have been confounded by the quality of the scans. The original scans had been printed out at PIER study sites and were subsequently scanned into portable document format for grading on a computer monitor. Moreover, only two upper-resolution scans were available per subject visit, rather than the six that are standard with a macular thickness map protocol on the Stratus OCT. High-resolution imaging with spectral-domain OCT will probably prove to be a more sensitive method for detecting recurrence of CNV leakage.
Our results demonstrate that subgroups of eyes that had no recurrent CNV leakage on FFA at Month 5 or OCT at Months 5 and 8 (visits 3 months after the last injection) maintained an overall net vision gain compared with baseline BCVA at the 24-month end point. In contrast, those with FFA and OCT activity at Months 3 (after 3 consecutive monthly doses), 5, or 8 not only lost the initial BCVA gains achieved but finished with net vision losses compared with baseline at the Month 24 end point. This association between specific anatomical markers and ultimate BCVA will need to be validated with the anatomical data sets available with the ongoing CATT and HARBOR PRN arms.
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